Treatment schedule for adult Ph+and/or BCR-ABL+ ALL: the LALA-94 trial
| Drug . | Dose . | Days . |
|---|---|---|
| Induction course | ||
| Prednisone, PO or IV | 60 mg/m2 | 1-7, 15-21 |
| Vincristine, IV | 2 mg | 1, 8, 15, 22 |
| Cyclophosphamide, IV | 750 mg/m2 | 1, 8 |
| Daunorubicin, IV* | 30 mg/m2 | 1-3, 15-16 |
| Idarubicin, IV* | 9 mg/m2 | 1-3, 8 |
| Methotrexate, IT | 15 mg | 1†, 8, 15, 22 |
| Cytosine arabinoside, IT | 40 mg | 1†, 8, 15, 22 |
| Methylprednisolone, IT | 40 mg | 1†, 8, 15, 22 |
| Consolidation/salvage course | ||
| Cytosine arabinoside, 3-h IV | 1 000 mg/m2/12 h | 1-4 (8 infusions) |
| Mitoxantrone, IV | 10 mg/m2 | 3-5 |
| Methotrexate, IT | 15 mg | 1 |
| Cytosine arabinoside, IT | 40 mg | 1 |
| Methylprednisolone, IT | 40 mg | 1 |
| Pretransplantation course(s)‡ | ||
| Methotrexate, IV | 1 500 mg/m2 | 1, +/− 15 |
| l-asparaginase, IV | 10 000 IU/m2 | 2, +/− 16 |
| HSCT1-153 | ||
| Etoposide, 6-h IV | 50 mg/kg | − 4 |
| Cyclophosphamide, 2-h IV | 60 mg/kg | − 3, − 2 |
| Total body irradiation | 12 Gy (6 fractions) or 10 Gy (1 fraction) |
| Drug . | Dose . | Days . |
|---|---|---|
| Induction course | ||
| Prednisone, PO or IV | 60 mg/m2 | 1-7, 15-21 |
| Vincristine, IV | 2 mg | 1, 8, 15, 22 |
| Cyclophosphamide, IV | 750 mg/m2 | 1, 8 |
| Daunorubicin, IV* | 30 mg/m2 | 1-3, 15-16 |
| Idarubicin, IV* | 9 mg/m2 | 1-3, 8 |
| Methotrexate, IT | 15 mg | 1†, 8, 15, 22 |
| Cytosine arabinoside, IT | 40 mg | 1†, 8, 15, 22 |
| Methylprednisolone, IT | 40 mg | 1†, 8, 15, 22 |
| Consolidation/salvage course | ||
| Cytosine arabinoside, 3-h IV | 1 000 mg/m2/12 h | 1-4 (8 infusions) |
| Mitoxantrone, IV | 10 mg/m2 | 3-5 |
| Methotrexate, IT | 15 mg | 1 |
| Cytosine arabinoside, IT | 40 mg | 1 |
| Methylprednisolone, IT | 40 mg | 1 |
| Pretransplantation course(s)‡ | ||
| Methotrexate, IV | 1 500 mg/m2 | 1, +/− 15 |
| l-asparaginase, IV | 10 000 IU/m2 | 2, +/− 16 |
| HSCT1-153 | ||
| Etoposide, 6-h IV | 50 mg/kg | − 4 |
| Cyclophosphamide, 2-h IV | 60 mg/kg | − 3, − 2 |
| Total body irradiation | 12 Gy (6 fractions) or 10 Gy (1 fraction) |
PO indicates per os; IV, intravenously; IT, intrathecally; HSCT, hematopoietic stem cell transplantation.
Patients received either daunorubicin or idarubicin, according to initial randomization.
The first IT infusion may be performed at day 1, 2, or 3.
Patients may receive 1 or 2 identical pretransplantation courses.
For allo-ID and autologous HSCT.